Drug Res (Stuttg) 2013; 63(08): 420-423
DOI: 10.1055/s-0033-1345109
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Platinum(IV) Complexes with Some Derivatives of 5-Methyl-5-(4-pyridyl)Hydantoin. Synthesis, Study and Comparative Pharmacological Investigation

A. Bakalova
1   Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
R. Buyukliev
1   Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
Z. Ivanova
1   Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
G. Momekov
2   Department of Pharmacology, Faculty of Pharmacy, Pharmacotherapy and Toxicology, Sofia, Medical University of Sofia, Bulgaria
D. Ivanov
1   Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
› Institutsangaben
Weitere Informationen


received 21. Februar 2013

accepted 29. März 2013

15. Mai 2013 (online)


3 Pt(IV) complexes with 3-ethyl-5-methyl-5-(4-pyridyl)hydantoin (4), 3-propyl-5-methyl-5-(4-pyridyl)hydantoin (5) and 3-benzyl-5-methyl-5-(4-pyridyl)hydantoin (6) with general formulae cis-[Pt(L)2Cl4] were synthesized. The novel compounds were characterized by elemental analysis, IR, 1H, 13C, NMR spectra in solid state and in solution. The studies showed that the ligands coordinate to the platinum ions in a monodentate manner through the nitrogen atom from the pyridine ring. The cytotoxic activity in vitro of newly synthesized complexes as well as their previously prepared analogous of Pt(IV) with other derivatives like 3-amino-5-methyl-5-(4-pyridyl)hydantoin (1), 5-methyl-5-(4-pyridyl)hydantoin (2), 3,5-dimethyl-5-(4-pyridyl)hydantoin (3) was screened against a panel of human tumor cell lines. The tested compounds displayed cytotoxic activity which was invariably superior with the Pt(IV) complex with 3-benzyl-5-methyl-5-(4-pyridyl)hydantoin (6) causing 50% inhibition of cellular viability at micromolar concentration, though the activity of the other studied Pt(IV) complexes proved to greatly decrease in the order 5-4-3-2-1.

  • References

  • 1 Florea A.-M, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers 2011; 3: 1351-1371
  • 2 Frezza M, Hindo S, Chen D et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des 2010; 16: 1813-1825
  • 3 Che C, Siu F. Metal complexes in medicine with a focus on enzyme inhibition. Curr Opin Chem Biol 2010; 14: 255-261
  • 4 Chen D, Milacic V, Frezza M et al. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des 2009; 15: 777-791
  • 5 Wheate N, Walker S, Craig G et al. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010; 39: 8113-8127
  • 6 USA Food and Drug Administration. 2007
  • 7 European Medicines Agency . 2008; 1-37
  • 8 Puszyńska-Tuszkanow M, Daszkiewicz M, Maciejewska G et al. Interaction of hydantoins with transition metal ions: synthesis, structural, spectroscopic, thermal and magnetic properties of [M(H2O)4(phenytoinate)2] M = Ni(II), Co(II). Struct Chem 2010; 21: 315-321
  • 9 Tabatabaei J, Shiraz N, Shafiee S et al. Synthesis and spectroscopic studies of Pt(II) and Ni(II) complex compounds with hydantoin derivatives. World Appl Sci J 2011; 13: 304-308
  • 10 Edsall J, Felsenfeld G, Goodman D et al. The association of imidazole with the ions of zinc and cupric copper. J Amer Chem Soc 1954; 76: 3054
  • 11 Kotton W, Dexter R, Clark R et al. Coordination Complexes and Catalytic Properties of Proteins and Related Substances. I. Effect of Cupric and Zinc Ions on the Hydrolysis of p-Nitrophenyl Acetate by Imidazole. J Amer Chem Soc 1958; 80: 4188
  • 12 Gupta V, Prasad R, Kumar A. A Preparation of ethambutol–copper(II) complex and fabrication of PVC based membrane potentiometric sensor for copper. Talanta 2003; 60: 149
  • 13 Varbanov H, Bakalova A, Buyukliev R et al. Synthesis of palladium(II) Complexes with 3-amino-5-methyl-5-(4-pyridyl)-hydantoin. Cytotoxic and Antimicrobial Investigations and Comparison with their Platinum Analogues. Trans Met Chem 2010; 35: 457-461
  • 14 Bakalova A, Varbanov H, Buyukliev R et al. Synthesis, Characterization and Biological Activity of Pt(II) and Pt(IV) Complexes with 5-methyl-5(4-pyridyl)-2,4-imidazolidenedione. Eur J Med Chem 2008; 43: 958-965
  • 15 Bakalova A, Varbanov H, Buyukliev R et al. Platinum Complexes with 5-methyl-5(4-pyridyl)hydantoin and its 3-methyl derivatives. Synthesis and Cytotoxic Activity. Quantitative Structure-Activity Relationships. Arch Pharm Chem Life Sci 2011; 11: 209-216
  • 16 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
  • 17 Konstantinov S, Eibl H, Berger M. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol 1999; 107: 365-374
  • 18 West D, Liberta A, Padhye S et al. Thiosemicarbazone complexes of copper(II): structural and biological studies. Coord Chem Rev 1993; 123: 49
  • 19 Pregosin P. Platinum-195 nuclear magnetic resonance. Coord Chem Rev 1982; 44: 247-291
  • 20 Chu Chin-Chiun Teague PC. 4-Pyridylhydantoins. J Org Chem 1958; 23: 1578
  • 21 Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. 3 Rev. ed. New York: John Wiley & Sons Inc; 1978: 197-206